API
< Back to all clusters
[BUSINESS] · South Korea, United States · 8 sources

started · updated

Lotte Biologics completes Songdo Bio Campus Plant 1

Lotte Biologics held a completion ceremony for its first biopharmaceutical manufacturing plant at the Songdo Bio Campus in Incheon, South Korea. The facility is a smart plant with a total capacity of 120,000 liters, featuring eight 15,000-liter stainless steel bioreactors and an automated robotic warehouse.

Ahead of the official completion, the company secured its first large-scale commercial contract with a global pharmaceutical client for direct production at the Songdo site. This follows a previous long-term agreement with Alvotech that utilized Lotte’s Syracuse, New York facility for initial production before transferring technology to Korea.

Lotte Group Chairman Shin Dong-bin stated that the bio business is a future growth engine for the conglomerate. Co-CEOs James Park and Shin Yoo-yeol emphasized the company’s goal to become a leading contract development and manufacturing organization (CDMO). The company aims to achieve annual sales of 1 trillion won by 2030, leveraging a dual-site strategy between its South Korean and U.S. facilities.

Entities

James Park · Lotte Biologics · Lotte Group · Shin Dong-bin · Shin Yoo-yeol · Shin Yu-yeol · Songdo Bio Campus